concise.news
SearchSign inGet the Brief
Today
‹ Today
8 ·Health8 ·Health

FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.

FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.

SourcesCBS News00:09 UTCMint10:18 UTCArs Technica14:43 UTCThe Independent15:22 UTCThe National16:59 UTCGlobal News18:17 UTCBBC18:43 UTCThe Guardian20:18 UTCBusinessLine07:01 UTCFollowSaveHighlight
CBS News, Mint, Ars Technica, The Independent, The National and 4 more

By concise.news.

Key points

From 4 outlets
  • FDA requires all GLP-1 medications to include NAION risk on labels. SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
  • NAION can cause sudden, painless vision loss and permanent blindness. SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The GuardianSourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine
  • Study data show higher NAION incidence in GLP-1 users than controls. SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
  • FDA reviewed 126 trials with over 134,200 patients to assess risk. SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
  • Pharma firms defend benefit-risk profile while monitoring safety and comment. SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
  • FDA instructed makers of Ozempic, Wegovy, Mounjaro, Zepbound to add NAION warnings. SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
  • Manufacturers dispute a proven cause-and-effect link but emphasize patient safety. SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
  • Warnings exist alongside other GLP-1 risks; researchers call for more study. SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
  • NAION is a rare eye condition caused by restricted blood flow to the optic nerve. SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
  • FDA reviews meta-analysis and studies, finding 15 probable NAION cases in trials. SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
  • Labeling will include a warning; providers may consider stopping GLP-1 therapy if NAION develops. SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
  • EMA and American ophthalmology groups similarly urge caution and shared decision-making. SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica

Why it matters. Patients with symptoms need prompt medical advice; providers may consider stopping treatment.

What to watch. Further research into cause and risk.

How it spread

At least 9 outlets ran it in the 36 h before this Brief. It was in the news before then.

051010 Nov06:0012:0018:0011 Nov06:009 outlets
  1. CBS News, 00:09 on Tuesday 10 November
  2. Mint, 10:18 on Tuesday 10 November
  3. Ars Technica, 14:43 on Tuesday 10 November
  4. The Independent, 15:22 on Tuesday 10 November
  5. The National, 16:59 on Tuesday 10 November
  6. Global News, 18:17 on Tuesday 10 November
  7. BBC, 18:43 on Tuesday 10 November
  8. The Guardian, 20:18 on Tuesday 10 November
  9. BusinessLine, 07:01 on Wednesday 11 November
Sourceconcise.newsEach outlet in Coverage, at its first report of this story in the 36 h before the Brief. Outlets that ran the same wire story each count.From each outlet’s feed

Coverage

Oldest first · UTC

“FDA warns of rare vision-loss side effect from GLP-1 drugs”

“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.”

Key points from CBS News
  • FDA requires a warning for all GLP-1 drugs, including Ozempic and Wegovy.
  • The eye condition NAION can cause partial or permanent vision loss.
  • FDA analysis: roughly 6 in 100,000 GLP-1 users for at least one year affected.
  • Placements of the warning followed a 2024 paper linking semaglutide to NAION.
  • Experts urge monitoring symptoms and consulting a healthcare professional promptly.
SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News

“FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know”

“FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.”

Key points from Mint
  • FDA warns of a rare eye condition NAION linked to GLP-1 receptor agonists.
  • Analysis found 15 probable NAION cases across 134,253 participants in trials.
  • Incidence: 6.4 per 100,000 person-years for GLP-1 RA users vs 3.8 for comparators.
  • Retrospective data show NAION rates around 30-32 per 100,000 in GLP-1 users.
  • Label updates will add warnings and precautions for GLP-1 RA products.
SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint

“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”

Key points from Ars Technica
  • FDA warns GLP-1 drugs like Ozempic and Wegovy may carry a rare NAION risk.
  • NAION is a rare eye condition caused by restricted blood flow to the optic nerve.
  • FDA reviews meta-analysis and studies, finding 15 probable NAION cases in trials.
  • Labeling will include a warning; providers may consider stopping GLP-1 therapy if NAION develops.
  • EMA and American ophthalmology groups similarly urge caution and shared decision-making.
SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica

“FDA adds rare blindness warning to popular GLP-1 drugs”

Key points from The Independent
  • FDA announced a new warning label for GLP-1 drugs including Ozempic, Wegovy, Zepbound, and Mounjaro.
  • The warning concerns non-arteritic anterior ischemic optic neuropathy, a rare cause of vision loss.
  • An FDA review followed a 2024 paper linking the condition to semaglutide use.
  • Analysis of over 125 trials showed about 6 in 100,000 patients affected for at least a year.
  • The rate is higher than the under 4 per 100,000 in placebo groups, per FDA data.
SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent

“FDA orders new warning on GLP-1 drugs over potential risk of blindness”

“The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must add a warning label about a possible link to permanent vision loss , the US Food and Drug Administration has said.”

Key points from The National
  • FDA orders new warning labels for GLP-1 drugs like Ozempic and Wegovy.
  • Warning cites potential link to permanent vision loss via NAION.
  • Decision based on clinical trials, observational studies, and 2024 article.
  • Healthcare providers urged to consider stopping GLP-1 if NAION signs appear.
  • Manufacturers must update labeling to reflect the potential risk.
SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National

“FDA to require vision loss warning on GLP-1 drug labels”

“The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.”

Key points from Global News
  • FDA will mandatorily add NAION risk to all GLP-1 drug labels.
  • Risk stems from a 2024 study and FDA trials reviewed by regulators.
  • NAION is a painless condition causing potential permanent vision loss.
  • Roughly 6 per 100,000 GLP-1 users for at least one year affected.
  • Canada also reviewed Ozempic, Rybelsus, Wegovy for NAION risk.
SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News

“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”

“The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.”

Key points from BBC
  • FDA instructed makers of Ozempic, Wegovy, Mounjaro, Zepbound to add NAION warnings.
  • NAION is a rare optic nerve blood flow blockage that can cause blindness.
  • FDA reviewed NAION reports and studies, noting increased risk with GLP-1 drugs.
  • Manufacturers dispute a proven cause-and-effect link but emphasize patient safety.
  • Warnings exist alongside other GLP-1 risks; researchers call for more study.
SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC

“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”

“The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels”

Key points from The Guardian
  • FDA requires all GLP-1 medications to include NAION risk on labels.
  • NAION can cause sudden, painless vision loss and permanent blindness.
  • Study data show higher NAION incidence in GLP-1 users than controls.
  • FDA reviewed 126 trials with over 134,200 patients to assess risk.
  • Pharma firms defend benefit-risk profile while monitoring safety and comment.
SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian

“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”

“These drugs may be associated with a drop in blood flow to the optic nerve which can cause sudden, painless loss of vision in one eye, and sometimes the damage is permanent, FDA said”

Key points from BusinessLine
  • FDA requires all GLP-1 receptor agonists to add warnings for NAION, a rare eye condition.
  • NAION can cause sudden, painless vision loss and may be permanent.
  • Meta-analysis: 15 probable NAION cases among 134,253 participants; GLP-1 users 6.4 per 100,000 person-years.
  • Real-world study: no risk rise versus SGLT-2 inhibitors; higher risk vs DPP-4 inhibitors.
  • Regulatory stance: evidence suggests possible increased risk but does not prove causation.
SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine

How it spread

At least 9 outlets ran it in the 36 h before this Brief. It was in the news before then.

051010 Nov12:0011 Nov9 outlets
  1. CBS News, 00:09 on Tuesday 10 November
  2. Mint, 10:18 on Tuesday 10 November
  3. Ars Technica, 14:43 on Tuesday 10 November
  4. The Independent, 15:22 on Tuesday 10 November
  5. The National, 16:59 on Tuesday 10 November
  6. Global News, 18:17 on Tuesday 10 November
  7. BBC, 18:43 on Tuesday 10 November
  8. The Guardian, 20:18 on Tuesday 10 November
  9. BusinessLine, 07:01 on Wednesday 11 November
Sourceconcise.newsEach outlet in Coverage, at its first report of this story in the 36 h before the Brief. Outlets that ran the same wire story each count.From each outlet’s feed

Coverage

Oldest first · UTC
SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News“FDA warns of rare vision-loss side effect from GLP-1 drugs”

“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.”

Key points from CBS News
  • FDA requires a warning for all GLP-1 drugs, including Ozempic and Wegovy.
  • The eye condition NAION can cause partial or permanent vision loss.
  • FDA analysis: roughly 6 in 100,000 GLP-1 users for at least one year affected.
  • Placements of the warning followed a 2024 paper linking semaglutide to NAION.
  • Experts urge monitoring symptoms and consulting a healthcare professional promptly.
SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint“FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know”

“FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than those taking placebos or other diabetes medications.”

Key points from Mint
  • FDA warns of a rare eye condition NAION linked to GLP-1 receptor agonists.
  • Analysis found 15 probable NAION cases across 134,253 participants in trials.
  • Incidence: 6.4 per 100,000 person-years for GLP-1 RA users vs 3.8 for comparators.
  • Retrospective data show NAION rates around 30-32 per 100,000 in GLP-1 users.
  • Label updates will add warnings and precautions for GLP-1 RA products.
SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
Key points from Ars Technica
  • FDA warns GLP-1 drugs like Ozempic and Wegovy may carry a rare NAION risk.
  • NAION is a rare eye condition caused by restricted blood flow to the optic nerve.
  • FDA reviews meta-analysis and studies, finding 15 probable NAION cases in trials.
  • Labeling will include a warning; providers may consider stopping GLP-1 therapy if NAION develops.
  • EMA and American ophthalmology groups similarly urge caution and shared decision-making.
SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent“FDA adds rare blindness warning to popular GLP-1 drugs”
Key points from The Independent
  • FDA announced a new warning label for GLP-1 drugs including Ozempic, Wegovy, Zepbound, and Mounjaro.
  • The warning concerns non-arteritic anterior ischemic optic neuropathy, a rare cause of vision loss.
  • An FDA review followed a 2024 paper linking the condition to semaglutide use.
  • Analysis of over 125 trials showed about 6 in 100,000 patients affected for at least a year.
  • The rate is higher than the under 4 per 100,000 in placebo groups, per FDA data.
SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National“FDA orders new warning on GLP-1 drugs over potential risk of blindness”

“The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must add a warning label about a possible link to permanent vision loss , the US Food and Drug Administration has said.”

Key points from The National
  • FDA orders new warning labels for GLP-1 drugs like Ozempic and Wegovy.
  • Warning cites potential link to permanent vision loss via NAION.
  • Decision based on clinical trials, observational studies, and 2024 article.
  • Healthcare providers urged to consider stopping GLP-1 if NAION signs appear.
  • Manufacturers must update labeling to reflect the potential risk.
SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News“FDA to require vision loss warning on GLP-1 drug labels”

“The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.”

Key points from Global News
  • FDA will mandatorily add NAION risk to all GLP-1 drug labels.
  • Risk stems from a 2024 study and FDA trials reviewed by regulators.
  • NAION is a painless condition causing potential permanent vision loss.
  • Roughly 6 per 100,000 GLP-1 users for at least one year affected.
  • Canada also reviewed Ozempic, Rybelsus, Wegovy for NAION risk.
SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”

“The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.”

Key points from BBC
  • FDA instructed makers of Ozempic, Wegovy, Mounjaro, Zepbound to add NAION warnings.
  • NAION is a rare optic nerve blood flow blockage that can cause blindness.
  • FDA reviewed NAION reports and studies, noting increased risk with GLP-1 drugs.
  • Manufacturers dispute a proven cause-and-effect link but emphasize patient safety.
  • Warnings exist alongside other GLP-1 risks; researchers call for more study.
SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”

“The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels”

Key points from The Guardian
  • FDA requires all GLP-1 medications to include NAION risk on labels.
  • NAION can cause sudden, painless vision loss and permanent blindness.
  • Study data show higher NAION incidence in GLP-1 users than controls.
  • FDA reviewed 126 trials with over 134,200 patients to assess risk.
  • Pharma firms defend benefit-risk profile while monitoring safety and comment.
SourceBusinessLineIndiaLeanUnratedCredibilityUnratedRead at BusinessLine“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”

“These drugs may be associated with a drop in blood flow to the optic nerve which can cause sudden, painless loss of vision in one eye, and sometimes the damage is permanent, FDA said”

Key points from BusinessLine
  • FDA requires all GLP-1 receptor agonists to add warnings for NAION, a rare eye condition.
  • NAION can cause sudden, painless vision loss and may be permanent.
  • Meta-analysis: 15 probable NAION cases among 134,253 participants; GLP-1 users 6.4 per 100,000 person-years.
  • Real-world study: no risk rise versus SGLT-2 inhibitors; higher risk vs DPP-4 inhibitors.
  • Regulatory stance: evidence suggests possible increased risk but does not prove causation.

AI wrote this story from the reports above. No person checked it before it was published. How concise.news works

How it travelled

Saudi Arabia’s press was first, at 11:10 on Tuesday 10 November.

and 8 more countries
  • A report of the story
  • A related report

Not drawn: El Comercio. It ran only copies.

  • In the story
    1. Elsewhere
      1. Saudi Arabia: 1 outlet, the first at 11:10 on Tuesday 10 November
        • Sabq, at 11:10 on Tuesday 10 November
      2. Iran: 1 outlet, the first at 11:14 on Tuesday 10 November
        • Ham-Mihan, at 11:14 on Tuesday 10 November
      3. Cyprus: 1 outlet, the first at 13:07 on Tuesday 10 November
        • Sigmalive, at 13:07 on Tuesday 10 November, a related report
      4. United States: 7 outlets, the first at 14:21 on Tuesday 10 November
        • The Washington Times, at 14:13 on Tuesday 10 November, a related report
        • CBS News, at 14:21 on Tuesday 10 November
        • STAT, at 14:38 on Tuesday 10 November
        • Ars Technica, at 14:43 on Tuesday 10 November
        • The Daily Beast, at 16:03 on Tuesday 10 November, a related report
        • La Opinion, at 17:01 on Tuesday 10 November
        • AP News, at 17:10 on Tuesday 10 November
      5. Brazil: 3 outlets, the first at 15:15 on Tuesday 10 November
        • Veja, at 15:15 on Tuesday 10 November, a related report
        • O Globo, at 15:46 on Tuesday 10 November, a related report
        • Metrópoles, at 18:42 on Tuesday 10 November, a related report
      6. United Kingdom: 3 outlets, the first at 15:22 on Tuesday 10 November
        • The Independent, at 15:22 on Tuesday 10 November; a related report at 14:35 on Tuesday 10 November
        • BBC, at 18:43 on Tuesday 10 November
        • The Guardian, at 20:18 on Tuesday 10 November
      7. United Arab Emirates: 1 outlet, the first at 16:59 on Tuesday 10 November
        • The National, at 16:59 on Tuesday 10 November
      8. Canada: 1 outlet, the first at 18:17 on Tuesday 10 November
        • Global News, at 18:17 on Tuesday 10 November
      9. India: 3 outlets, the first at 18:46 on Tuesday 10 November
        • Mathrubhumi, at 12:52 on Tuesday 10 November, a related report
        • The Economic Times, at 18:46 on Tuesday 10 November
        • BusinessLine, at 07:01 on Wednesday 11 November
      10. Israel: 1 outlet, the first at 19:29 on Tuesday 10 November
        • Srugim, at 19:29 on Tuesday 10 November, a related report
      11. Australia: 1 outlet, the first at 23:07 on Tuesday 10 November
        • The Conversation, at 23:07 on Tuesday 10 November
      12. Malaysia: 1 outlet, the first at 01:30 on Wednesday 11 November
        • Utusan Malaysia, at 01:30 on Wednesday 11 November
      13. South Korea: 3 outlets, the first at 05:07 on Wednesday 11 November
        • Chosun Ilbo, at 15:31 on Tuesday 10 November, a related report
        • SBS News, at 15:45 on Tuesday 10 November, a related report
        • The Korea Times, at 05:07 on Wednesday 11 November
      14. Greece: 1 outlet, the first at 10:07 on Wednesday 11 November
        • ERTnews, at 10:07 on Wednesday 11 November
      15. Hong Kong: 1 outlet, the first at 11:00 on Wednesday 11 November
        • Sing Tao Headline, at 11:00 on Wednesday 11 November
      16. Taiwan: 1 outlet, the first at 12:26 on Wednesday 11 November
        • PTS News, at 12:26 on Wednesday 11 November, a related report
    Sourceconcise.newsEach outlet’s first report of this story, by its country.Reports from 24 h before the Brief to 48 h after.Found after the Brief picked its stories. They don’t change its ranking.From each outlet’s feedPress freedom: RSF World Press Freedom Index 2026Checked 17:34 on Wednesday 11 November

    Why it’s in the Brief

    Ranked 8th of 10.

    Starting score
    5.0
    Public-interest topic
    +1.0
    Public-interest terms in the text
    +1.25
    High-reliability sources
    +0.75
    Corroboration by independent outlets
    +0.8
    Score
    8.8

    The ranking is the same for everyone.

    Perspective mix. 3 center-left · 2 center · 4 unrated.RatingsAllSides and Media Bias/Fact CheckLean and credibility are curated from their public ratings.Unknown outlets stay unrated, never guessed.

    Blindspot. No right-leaning outlet is covering this story. Worth knowing before you make up your mind.

    Earlier

    From the archive

    In the Brief of Tuesday 10 November

    Earlier

    From the archive

    In the Brief of Tuesday 10 November

    More from today’s Brief